.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing advanced endometrial cancer requires a multidisciplinary approach. A recent study highlights the potential of using IGBT for endometrial cancer in patients with inoperable stage IVB disease. While palliative care is often the only route, findings suggest that image-guided brachytherapy (IGBT), with or without external-beam irradiation (EBRT), significantly improves survival for some. Therefore, clinicians should evaluate these local treatment options for patients showing good responses to initial chemotherapy.
The research analyzed outcomes for 11 patients diagnosed with FIGO 2009 stage IVB endometrial cancer. These patients were not candidates for palliative surgery. Among them, several patients exhibited metastases in locations such as the lungs, liver, and bone. Consequently, most patients underwent chemotherapy before starting radiation treatments. Five individuals achieved a complete response after systemic therapy. Nine patients received a combination of EBRT and IGBT, while two received IGBT as a standalone treatment. Throughout the follow-up period, the researchers monitored disease evolution and survival rates closely.
The clinical outcomes revealed surprisingly high survival rates for such an advanced stage. At two and three years, the overall survival (OS) reached 69.3%. Furthermore, the 5 and 10-year survival rates remained stable at 41.6%. These results indicate that local-regional control plays a vital role even in metastatic disease. However, patients who developed uterine or lymph node relapses faced poor prognoses. Consequently, doctors should prioritize this aggressive local strategy for those who respond well to chemotherapy. Future prospective trials including biological markers will help refine these therapeutic protocols.
IGBT for endometrial cancer provides precise, high-dose radiation to the tumor site. This helps achieve better local control, which is linked to improved overall survival in patients who have already responded well to systemic chemotherapy.
Patients with inoperable stage IVB disease who show a complete or good response to chemotherapy are the primary candidates. The treatment aims to consolidate the response and prevent local relapse.
In this specific series, patients achieved a 5-year overall survival rate of 41.6%. This is significantly higher than historical averages for stage IVB disease treated with palliative care alone.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and is not intended to be a substitute for professional medical diagnosis, treatment, or clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Analysis of IGBT outcomes in 11 patients with stage IVB endometrial cancer, showing a 41.6% 10-year survival rate for chemotherapy responders....
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
